menu

Navigating Complex Patients with Parkinson’s Disease Psychosis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Navigating Complex Patients with Parkinson’s Disease Psychosis

0.75 credits
30-45 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Psychosis is an often-challenging complication of Parkinson’s disease. Neurologist Dr Daniel Claassen and Psychiatrist Dr Gregory Pontone will take you through an interactive patient simulation, sharing their approaches to the management of a more complex patient. You will follow this patient over the course of a few years as her disease progresses and decide on the optimal paths to take in making her diagnosis and recommending treatment. You will learn about the latest guidelines and evidence underlying current best practice. 

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

    Faculty
    Daniel Claassen, MD, is a consultant for Alterity Therapeutics and Spark Therapeutics, Inc; and is a contracted researcher for Alterity Therapeutics and, CHDI Foundation, Inc, F. Hoffman-La Roche Ltd, Genentech, Inc, Prilenia Therapeutics, and Vaccinex Inc.

    Gregory Pontone, MD, MHS, is a consultant for ACADIA Pharmaceuticals Inc and Cerevance.

    Peer Reviewer
    This activity was peer reviewed. The peer reviewer has no relevant financial relationships. 

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This activity intends to educate neurologists, psychiatrists, and primary care clinicians caring for patients with PDP.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Integrate routine screening for symptoms of psychosis in patients with PD into practice
    • Develop individualized, evidence-based care plans for persons with PDP
  • Accreditation and Credit Designation Statements

    For Physicians:
    Accreditation Statement

    MedEdicus LLC is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation Statement
    MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For Nurses:
    Interprofessional Joint Accreditation Statement

    In support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nursing Credit
    The maximum number of hours awarded for this Continuing Nursing Education Activity is 0.75 contact hour.

  • Disclaimer

    Instructions for Obtaining Credit
    To obtain CME/CE credit for this activity, please listen to the podcast, consult referenced sources as necessary, and complete the posttest and evaluation online. Upon passing, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

    Disclaimer
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.2

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

    To view the MedEdicus Privacy Policy, click here

  • Commercial Support

    This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Psychosis is an often-challenging complication of Parkinson’s disease. Neurologist Dr Daniel Claassen and Psychiatrist Dr Gregory Pontone will take you through an interactive patient simulation, sharing their approaches to the management of a more complex patient. You will follow this patient over the course of a few years as her disease progresses and decide on the optimal paths to take in making her diagnosis and recommending treatment. You will learn about the latest guidelines and evidence underlying current best practice. 

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

    Faculty
    Daniel Claassen, MD, is a consultant for Alterity Therapeutics and Spark Therapeutics, Inc; and is a contracted researcher for Alterity Therapeutics and, CHDI Foundation, Inc, F. Hoffman-La Roche Ltd, Genentech, Inc, Prilenia Therapeutics, and Vaccinex Inc.

    Gregory Pontone, MD, MHS, is a consultant for ACADIA Pharmaceuticals Inc and Cerevance.

    Peer Reviewer
    This activity was peer reviewed. The peer reviewer has no relevant financial relationships. 

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This activity intends to educate neurologists, psychiatrists, and primary care clinicians caring for patients with PDP.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Integrate routine screening for symptoms of psychosis in patients with PD into practice
    • Develop individualized, evidence-based care plans for persons with PDP
  • Accreditation and Credit Designation Statements

    For Physicians:
    Accreditation Statement

    MedEdicus LLC is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation Statement
    MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For Nurses:
    Interprofessional Joint Accreditation Statement

    In support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nursing Credit
    The maximum number of hours awarded for this Continuing Nursing Education Activity is 0.75 contact hour.

  • Disclaimer

    Instructions for Obtaining Credit
    To obtain CME/CE credit for this activity, please listen to the podcast, consult referenced sources as necessary, and complete the posttest and evaluation online. Upon passing, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

    Disclaimer
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.2

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

    To view the MedEdicus Privacy Policy, click here

  • Commercial Support

    This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule4 Dec 2022